Cargando…

Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public–private hospital partnership during the 2022 NYC mpox outbreak

During the 2022 mpox outbreak, tecovirimat was accessed through an expanded access investigational new drug (EA-IND) protocol. We leveraged a unique public/private hospital partnership in New York City to create a novel infrastructure to navigate the EA-IND’s regulatory requirements and rapidly prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mgbako, Ofole, Chan, Justin, Pitts, Robert A., DiLorenzo, Madeline A., Knutsen, Dorothy, Mazo, Dana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369430/ https://www.ncbi.nlm.nih.gov/pubmed/37502253 http://dx.doi.org/10.1017/ash.2023.194

Ejemplares similares

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
por: Smith, Todd G., et al.
Publicado: (2023)

Tecovirimat for the treatment of severe Mpox in Germany
por: Hermanussen, Lennart, et al.
Publicado: (2023)

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
por: Contag, Caitlin A., et al.
Publicado: (2023)

1790. Characteristics of Patients with Mpox Treated with Tecovirimat during the 2022 Outbreak in Puerto Rico
por: Gonzalez, Hector J Melendez, et al.
Publicado: (2023)

Tecovirimat use among patients with monkeypox (mpox) in Alameda County, California, June–October 2022
por: Ouyang, Megan, et al.
Publicado: (2023)

Critical Elements of an Mpox Vaccination Model at the Largest Public Health Hospital System in the United States
por: Piccolo, Anthony J. Lo, et al.
Publicado: (2023)

Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA
por: Lash, Maura K., et al.
Publicado: (2023)

2684. Characteristics of mpox patients treated with Tecovirimat: a single center review
por: Vargas, Robert, et al.
Publicado: (2023)

Finding hope in two pandemics
por: Mgbako, Ofole
Publicado: (2022)

Tecovirimat for Monkeypox in the Central African Republic under Expanded Access
por: Mbrenga, Festus, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System
por: Vo, Christopher, et al.
Publicado: (2023)

Tecovirimat for monkeypox
por: Halani, Sheliza, et al.
Publicado: (2022)

1629. Acceptability and Trust in the Low-dose Intradermal Mpox Vaccine: a Knowledge, Attitudes and Practices Sub-analysis of the Observational Study of Mpox Immunity (OSMI) in NYC
por: Carmody, Ellie, et al.
Publicado: (2023)

Monkeypox treatment: Is tecovirimat the answer?
por: Niaz, Faizan, et al.
Publicado: (2022)

Bictegravir-Induced Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Acute Human Immunodeficiency Virus
por: DiLorenzo, Madeline A, et al.
Publicado: (2023)

Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report
por: Martinez, Andres E., et al.
Publicado: (2023)

Nowcasting the 2022 mpox outbreak in England
por: Overton, Christopher E., et al.
Publicado: (2023)

897. Patients with Mpox, Minnesota, 2022
por: Lehnertz, Nicholas, et al.
Publicado: (2023)

Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse
por: Ahuja, Tania, et al.
Publicado: (2018)

Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak
por: Perzia, Brittany, et al.
Publicado: (2022)

Recombination shapes the 2022 monkeypox (mpox) outbreak
por: Yeh, Ting-Yu, et al.
Publicado: (2022)

Public-Private Partnerships
por: Yescombe, E
Publicado: (2011)

LB13. Candida auris in NYC: A Health System’s Experience Treating the Emerging Drug-Resistant Yeast
por: Mazo, Dana, et al.
Publicado: (2018)

Complete Resolution of Tumor Burden of Primary Cardiac Non-Hodgkin's Lymphoma
por: Mauricio, Rina, et al.
Publicado: (2016)

Overview of Mpox Outbreak in Greece in 2022–2023: Is It Over?
por: Mellou, Kassiani, et al.
Publicado: (2023)

Epidemiological and clinical characteristics of Mpox Cases in Serbia in 2022
por: Jovanovic, V, et al.
Publicado: (2023)

Treatment with tecovirimat of the first two cases of monkeypox in Japan
por: Inada, Makoto, et al.
Publicado: (2023)

Monkeypox Proctitis: A Case of Targeted Treatment With Tecovirimat
por: Patel, Premalkumar, et al.
Publicado: (2023)

Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022
por: Vallejo-Plaza, Alberto, et al.
Publicado: (2022)

Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022
por: O’Laughlin, Kevin, et al.
Publicado: (2022)

Impact of airline network on the global importation risk of mpox, 2022
por: Kinoshita, Ryo, et al.
Publicado: (2023)

Results of PCR Analysis of Mpox Clinical Samples, Sweden, 2022
por: Edman-Wallér, Jon, et al.
Publicado: (2023)

Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022
por: Garba-Ouangole, Sandra, et al.
Publicado: (2023)

Mpox in Children and Adolescents during Multicountry Outbreak, 2022–2023
por: Hoxha, Ana, et al.
Publicado: (2023)

The CDC Domestic Mpox Response — United States, 2022–2023
por: McQuiston, Jennifer H., et al.
Publicado: (2023)

Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat
por: Hernandez, Loren E, et al.
Publicado: (2022)

“Like a ticking time bomb”: the persistence of trauma in the HIV diagnosis experience among black men who have sex with men in New York City
por: Mgbako, Ofole, et al.
Publicado: (2020)

1495. Mpox Vaccine Immunity in People Living with HIV (PLWH) During The 2022 Mpox Outbreak in New York City
por: Kottkamp, Angelica C, et al.
Publicado: (2023)

Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge()()
por: Russo, Andrew T., et al.
Publicado: (2020)

Legislation: NYC Adopts Pesticide Laws
por: Claudio, Luz
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4aiv79bnmtvhf4jqphg9tjb3ij